Corvus Pharmaceuticals Inc

Uždarymo kaina

15.25 2.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.77

Max

15.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+107.49% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-199M

1.1B

Ankstesnė atidarymo kaina

12.42

Ankstesnė uždarymo kaina

15.25

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-04 23:51; UTC

Macro News
Correlated Moves

Bitcoin is higher as the Trump administration advances plans for a Strategic Bitcoin Reserve, with a federal purchase expected by Q4 2026.

2026-07-04 23:41; UTC

Canada's Balance of Trade data set for July 7, 2026, forecasts a C$2.4 billion surplus amid cautious market optimism despite geopolitical tensions and U.S.-Canada trade concerns.

2026-07-04 23:41; UTC

Brazil's July Inflation Rate Release Sparks Caution Amid Mixed Economic Signals and Global Monetary Policy Shifts

2026-07-04 23:41; UTC

Brazil's June 2026 Inflation Rate Release Sparks Cautious Optimism Amid Easing Pressures and Global Economic Influences

2026-07-04 23:41; UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected to Influence Market Sentiment Amid Global Economic Trends.

2026-07-04 23:41; UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Resilience Amid Geopolitical Tensions and Market Optimism Following Record Highs

2026-07-04 23:41; UTC

Mexico's Inflation Rate MoM Release on July 9 Expected to Reflect Global Economic Pressures Amid U.S. Monetary Policy Concerns.

2026-07-04 23:41; UTC

U.S. Imports Data Release on July 7, 2026: Market Anticipates Impact of Tariffs and Global Trade Dynamics Amid Cautious Optimism for Economic Stabilization.

2026-07-04 23:41; UTC

U.S. Trade Deficit Expected at $78.8 Billion Amid Weak Job Growth and Easing Geopolitical Tensions

2026-07-04 23:32; UTC

Cryptocurrency Market Gains Amid Weak U.S. Job Data and Cautious Fed Outlook

2026-07-04 23:32; UTC

Bitcoin and Ethereum rise amid positive market sentiment following disappointing U.S. jobs data and easing geopolitical tensions, while investors anticipate key economic releases next week.

2026-07-04 23:32; UTC

U.S. job growth disappoints, shifting Fed rate hike expectations, while Eurozone PMI stabilizes and car registrations surge in Germany.

2026-07-04 23:32; UTC

Cryptocurrency market shows recovery as Bitcoin and Ethereum post gains, while U.S. job growth disappoints, reducing Fed rate hike expectations ahead of July FOMC meeting.

2026-07-04 23:21; UTC

Macro News
Correlated Moves

Ethereum is advancing today, buoyed by Federal Reserve Chair Kevin Warsh's remarks on easing inflation risks and strong market interest ahead of Pepeto's presale.

2026-07-04 23:11; UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a decline since Friday's close amid limited momentum and macroeconomic influences.

2026-07-04 23:11; UTC

Correlated Moves

After-market trading for the Dow Jones Index shows a decline, reflecting a cumulative drop since Friday's close amid shared macroeconomic factors with the S&P 500.

2026-07-04 23:01; UTC

The FTSE 100 Index is lower in after-hours trading, reversing earlier gains. It remains above its 20-day moving average and near its one-month range.

2026-07-04 23:01; UTC

Correlated Moves

Cardano is rising, supported by Ethereum's gains and positive market sentiment. The asset remains above its 20-day moving average, with strong performance over four sessions.

2026-07-04 23:01; UTC

Macro News

The S&P 500 Index is lower in after-market hours amid rising memory chip costs and escalating geopolitical tensions following a Ukrainian drone attack.

2026-07-04 23:01; UTC

The Nasdaq 100 Index is lower in after-hours trading, continuing a decline since Friday's close without any specific news to explain the movement.

2026-07-04 22:51; UTC

Brazil's Retail Sales MoM data set for July 8, 2026, shows cautious optimism as analysts predict recovery from April’s -1.5% decline amid positive economic sentiment linked to World Cup events.

2026-07-04 22:51; UTC

The DAX 30 Index is trading lower in after-market hours, reflecting a decline since Friday's close and contrasting with recent upward momentum.

2026-07-04 22:41; UTC

Cautious Optimism Grows Ahead of MBA Mortgage Rate Release Amid Easing Inflation and Weaker Jobs Data

2026-07-04 22:31; UTC

Japan's Current Account Data Release on July 7, 2026, Forecasts JPY 4.12 Trillion Surplus Amid Market Volatility and Global Economic Concerns.

2026-07-04 22:31; UTC

Brazil's Central Bank to Discuss SELIC Rate Amid Mixed Economic Signals and Global Influences on July 6, 2026.

2026-07-04 22:11; UTC

UK Housing Market Faces Continued Downward Pressure as RICS House Price Balance Forecasts -0.32% Amid Economic Challenges

2026-07-04 21:51; UTC

Japan's Household Spending YoY data set for July 6, 2026, expected to decline amid cautious market sentiment and global economic pressures.

2026-07-04 21:51; UTC

Japan's Household Spending Expected to Rise 1.4% in May Amid Mixed Economic Sentiment and Positive Service Sector Growth

2026-07-04 21:01; UTC

Macro News

Brent crude prices are lower in after-market hours following a Ukrainian drone attack on an oil terminal in St. Petersburg, intensifying the fuel crisis in Russia.

2026-07-04 20:21; UTC

ECB President Lagarde's upcoming speech sparks cautious market sentiment on Eurozone interest rate hikes amid easing inflation pressures.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

107.49% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  107.49%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat